LeonaBio's ELAINE-3 Bets on Two Unproven Hypotheses With a 2.7-Quarter Cash Runway

LeonaBio Advances Phase 3 Lasofoxifene Trial, Reports Q2 2026 Financials

LeonaBio, Inc. reported its second quarter 2026 financial results and provided a business update, primarily focusing on the advancement of its lead oncology program. The company is on track to complete enrollment of approximately 600 participants in the Phase 3 ELAINE-3 clinical trial of lasofoxifene by the fourth quarter of 2026, with topline data anticipated in the second half of 2027. Lasofoxifene, a selective estrogen receptor modulator, is being evaluated in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer. As of June 30, 2026, LeonaBio held $51.1 million in cash, cash equivalents, and investments, reporting a net loss of $19.0 million for the quarter. The company also highlighted its neurodegenerative program, brelgometon, and recent board appointments.

• LeonaBio is progressing well with its pivotal Phase 3 ELAINE-3 trial (NCT05696626) for lasofoxifene, a novel SERM, in combination with abemaciclib. The trial targets ER+, HER2-negative, ESR1-mutated metastatic breast cancer patients who have progressed on prior therapies. With 495 patients already enrolled, the company expects to complete enrollment of approximately 600 participants by Q4 2026 and release topline data in H2 2027, aiming to establish a new standard of care.
• Lasofoxifene has demonstrated promising results in earlier Phase 2 studies (ELAINE-1 and ELAINE-2). ELAINE-1 showed improved outcomes as monotherapy compared to fulvestrant, including longer median PFS (5.6 vs. 3.7 months) and higher ORR (13.3% vs. 2.9%). ELAINE-2, evaluating the combination with abemaciclib, achieved a median PFS of approximately 13 months, an ORR of 56%, and a clinical benefit rate of 65.5% in heavily pretreated patients, supporting its potential in this difficult-to-treat population.
• As of June 30, 2026, LeonaBio reported a cash position of $51.1 million. The company's R&D expenses increased to $12.9 million for Q2 2026, primarily due to the ELAINE-3 trial, contributing to a net loss of $19.0 million. Strategically, LeonaBio acquired global rights to lasofoxifene from Sermonix Pharmaceuticals in December 2025 and recently strengthened its Board of Directors with three new appointments, enhancing its governance and operational capabilities.

Addressing Unmet Needs in ESR1-Mutated Metastatic Breast Cancer

ESR1 mutations present a multifaceted clinical challenge in ER+/HER2− metastatic breast cancer, complicating both detection and therapeutic decision-making. The biological and genomic complexity of this patient population limits the effectiveness of standard endocrine strategies and underscores the need for more targeted approaches.

• Detection variability across methodologies and sample types: Accurate ESR1 mutation identification is complicated by significant differences in detection rates depending on sample source — CTC-derived genomic DNA yields higher detection rates (26.2%) compared to paired plasma cell-free DNA (14.3%). The transient nature of cfDNA further demands meticulous sample handling and timely analysis. At the assay level, ddPCR offers superior analytical sensitivity for hotspot mutations, while NGS provides broader mutational coverage, meaning no single method is universally optimal.

• Acquired endocrine resistance driven by ESR1 mutations: ESR1 mutations represent a biologically distinct mechanism of endocrine resistance rather than a simple treatment escape. Approximately 40% of patients receiving first-line CDK4/6 inhibitor plus aromatase inhibitor (AI) therapy develop acquired ESR1 mutations, which confer ligand-independent estrogen receptor activation and render continued AI-based therapy ineffective.

• Inadequate efficacy of existing therapeutic options: Fulvestrant, the first approved selective estrogen receptor degrader and the established second-line endocrine standard of care, is constrained by intramuscular administration and poor bioavailability. Clinical outcomes in heavily pretreated ESR1-mutated patients remain poor — in one reported cohort, only 1 of 5 fulvestrant-treated patients achieved stable disease (for 8 months), while the remaining 4 experienced disease progression.

• Co-occurring genomic alterations that complicate treatment selection: ESR1 mutations rarely occur in isolation. In one cohort, 67.9% of patients harboring ESR1 mutations carried three or more additional genomic alterations, and 25% carried one or two co-alterations — a complex mutational landscape that may influence therapeutic response and significantly complicates the selection of subsequent treatment strategies.

ELAINE-3: Designing a New Standard for ESR1-Mutated mBC

The landscape of ESR1-mutated ER+/HER2-negative metastatic breast cancer (mBC) has been shaped by a series of randomized trials evaluating oral selective estrogen receptor degraders (SERDs) against standard endocrine therapy. A systematic review and meta-analysis consolidating six of these randomized trials — encompassing 2,808 patients with HR+/HER2-negative advanced breast cancer following prior endocrine therapy — provides a comprehensive view of design parameters and outcomes across this drug class.

Lasofoxifene's Clinical Profile and Prior Efficacy Data

Recent clinical trials have significantly advanced the treatment landscape for ER+, HER2-negative, ESR1-mutated metastatic breast cancer, establishing targeted endocrine strategies as viable alternatives to standard-of-care regimens. The studies below highlight key efficacy and safety findings across distinct intervention modalities.

• EMERALD Trial (Elacestrant vs. standard-of-care endocrine monotherapy): Elacestrant, an oral selective estrogen receptor degrader (SERD), demonstrated improved median progression-free survival versus fulvestrant or aromatase inhibitor in the intention-to-treat population, with the benefit predominantly driven by the ESR1-mutated cohort. Based on these findings, the FDA approved elacestrant on January 27, 2023, for ER/PR-positive, HER2-negative metastatic breast cancer harboring an ESR1 missense mutation following at least one prior line of endocrine therapy.

• RAD1901-005 Phase I Study (Elacestrant 400 mg orally once daily): In patients with ESR1 mutations, elacestrant at the recommended Phase II dose (RP2D) achieved an objective response rate of 33.3% (n = 5/15) and a 24-week clinical benefit rate of 56.5% (n = 23); clinical benefit was associated with a measurable decline in ESR1 mutant allele fraction. No dose-limiting toxicities were observed, and the most common adverse events were nausea (33.3%), increased blood triglycerides (25.0%), and decreased blood phosphorus (25.0%), with the majority of events grade 1–2 in severity.

• SERENA-6 Trial (Camizestrant 75 mg once daily plus CDK4/6 inhibitor vs. aromatase inhibitor plus CDK4/6 inhibitor): In patients with emerging ESR1 mutations detected during first-line therapy, camizestrant yielded a median progression-free survival of 16.0 months (95% CI, 12.7–18.2) compared with 9.2 months (95% CI, 7.2–9.5) in the aromatase inhibitor arm (HR 0.44; 95% CI, 0.31–0.60; P<0.0001). Patient-reported outcomes also favored camizestrant, with median time to deterioration in global health status and quality of life of 23.0 months versus 6.4 months (HR 0.53; 95% CI, 0.33–0.82). The safety profile was favorable, with treatment discontinuation due to adverse events occurring in only 1.3% of camizestrant-treated patients versus 1.9% in the aromatase inhibitor group.

Lasofoxifene's Potential in an Evolving mBC Landscape

Over the past five years, the treatment paradigm for ER+/HER2−, ESR1-mutated metastatic breast cancer has been fundamentally reshaped by the clinical validation and regulatory approval of oral selective estrogen receptor degraders (SERDs). The pivotal EMERALD phase III trial marked a defining moment: elacestrant, administered at 400 mg orally once daily, demonstrated statistically significant superiority over standard endocrine monotherapy in patients who had received one to two prior lines of endocrine therapy inclusive of a CDK4/6 inhibitor. In the overall trial population, elacestrant achieved a progression-free survival hazard ratio of 0.70 (95% CI, 0.55–0.88; P = .002), with the benefit substantially amplified in the ESR1-mutant subgroup (47.8% of enrolled patients), where the hazard ratio was 0.55 (95% CI, 0.39–0.77; P = .0005). These data supported regulatory approvals from the FDA, EMA, and MHRA, and subsequent incorporation into ESMO and ASCO clinical guidelines — establishing elacestrant as the first oral SERD to achieve formal recognition as a standard-of-care option for this molecularly defined population.

Prior to these advances, fulvestrant — an intramuscular SERD with well-characterized limitations in bioavailability and ER target engagement — represented the principal monotherapy option for patients progressing on first-line CDK4/6 inhibitor-based regimens. ESR1 mutations, which accrue under the selective pressure of aromatase inhibitor therapy and are significantly enriched in patients exposed to CDK4/6 inhibitors per real-world data from 3,958 ER+ metastatic breast cancer patients, confer ligand-independent receptor activation and direct resistance to fulvestrant. Pharmacodynamic data from the RAD1901-106 phase Ib study demonstrated that elacestrant achieved a median 89.1% reduction in tumor FES uptake by FES-PET/CT at day 14, underscoring meaningful ER target occupancy even in heavily pretreated patients with a median 2.5 prior lines of endocrine therapy. Preclinical evidence further illustrated the mechanistic complexity of ESR1-driven resistance, with engineered MCF7 xenografts harboring Y537S and D538G mutations exhibiting resistance to palbociclib, and compound ESR1 mutations — including D538G+F404L and E380Q+F404L — conferring fulvestrant resistance while remaining susceptible to next-generation oral ER degraders.

The investigational pipeline has expanded considerably beyond elacestrant, with multiple next-generation agents advancing through early-phase development. Camizestrant, an oral selective ER antagonist and degrader with an estimated half-life of 20–23 hours supporting once-daily dosing, demonstrated efficacy across all doses evaluated in the SERENA-1 phase I study — including in patients with prior CDK4/6 inhibitor and fulvestrant exposure, across ESR1 mutation status, and in the setting of visceral metastases. Vepdegestrant (ARV-471), an oral PROTAC-based ER degrader, induced ≥90% degradation of both wild-type and mutant ER in preclinical models, with tumor growth inhibition of 87–123% in MCF7 orthotopic xenografts — outperforming fulvestrant — and demonstrated activity in palbociclib-resistant ESR1 Y537S patient-derived xenograft models. Underpinning clinical implementation across this evolving landscape is the increasing utilization of liquid biopsy for circulating tumor DNA analysis, enabling real-time ESR1 mutation monitoring; however, clinical adoption remains constrained by low ctDNA levels, technological variability, and the absence of standardized clinical thresholds.

Pivotal Phase 3 for Lasofoxifene in ESR1-Mutated Breast Cancer

The landscape of ER-positive, HER2-negative metastatic breast cancer (mBC) is constantly evolving, yet a significant challenge remains for patients whose disease progresses after initial therapies, particularly those with acquired ESR1 mutations. These mutations are a well-established driver of endocrine resistance, leaving limited effective treatment options. LeonaBio's advancement of its lead oncology program, lasofoxifene, into the pivotal Phase 3 ELAINE 3 trial, represents a high-stakes effort to address this critical unmet need.

Lasofoxifene, a next-generation selective estrogen receptor modulator (SERM), has shown promising preclinical and Phase 2 clinical activity. In the ELAINE 2 study, the combination of lasofoxifene with abemaciclib demonstrated meaningful antitumor activity, including a 65.5% clinical benefit rate and a 55.6% objective response rate in patients with ESR1-mutated mBC who had progressed on prior CDK4/6 inhibitors. Crucially, this activity was accompanied by a reduction in ESR1-mutant circulating tumor DNA, suggesting effective target engagement.

If the ELAINE 3 trial, comparing lasofoxifene/abemaciclib to fulvestrant/abemaciclib, confirms these positive findings, it could establish a new standard of care for this resistant patient population. This would not only validate LeonaBio's strategic focus and potentially secure a vital revenue stream but also reignite interest in the targeted development of SERMs for specific breast cancer subtypes.

However, the path forward is not without its considerations. The ELAINE 1 trial, which evaluated lasofoxifene monotherapy against fulvestrant, did not show a statistically significant progression-free survival benefit, setting a high bar for the ELAINE 3 combination to demonstrate clear superiority. Furthermore, emerging research suggests that complex dual mutations in the estrogen receptor alpha ligand-binding domain could potentially reduce lasofoxifene's efficacy, posing a future challenge. Finally, as with all SERMs, the known class-specific adverse effects, such as hot flushes and the risk of venous thromboembolic events, will require careful management in a chronic treatment setting. Despite these considerations, the potential for a new, targeted therapy for ESR1-mutated mBC makes ELAINE 3 a trial to watch closely.